Literature DB >> 21330576

Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment.

N Vande Casteele, V Ballet, G Van Assche, P Rutgeerts, S Vermeire, A Gils.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21330576     DOI： 10.1136/gut.2010.236869

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  13 in total

Review 1.  Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.

Authors:  Weiwei Jiang; Xuhang Li
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

2.  Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab.

Authors:  Sumin Bian; Marc Ferrante; Ann Gils
Journal:  AAPS J       Date:  2016-11-21       Impact factor: 4.009

Review 3.  Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide.

Authors:  Philip Hendy; Ailsa Hart; Peter Irving
Journal:  Frontline Gastroenterol       Date:  2015-01-21

4.  Assays for measurement of TNF antagonists in practice.

Authors:  Niels Vande Casteele
Journal:  Frontline Gastroenterol       Date:  2016-03-08

5.  Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study.

Authors:  Subra Kugathasan; Lee A Denson; Thomas D Walters; Mi-Ok Kim; Urko M Marigorta; Melanie Schirmer; Kajari Mondal; Chunyan Liu; Anne Griffiths; Joshua D Noe; Wallace V Crandall; Scott Snapper; Shervin Rabizadeh; Joel R Rosh; Jason M Shapiro; Stephen Guthery; David R Mack; Richard Kellermayer; Michael D Kappelman; Steven Steiner; Dedrick E Moulton; David Keljo; Stanley Cohen; Maria Oliva-Hemker; Melvin B Heyman; Anthony R Otley; Susan S Baker; Jonathan S Evans; Barbara S Kirschner; Ashish S Patel; David Ziring; Bruce C Trapnell; Francisco A Sylvester; Michael C Stephens; Robert N Baldassano; James F Markowitz; Judy Cho; Ramnik J Xavier; Curtis Huttenhower; Bruce J Aronow; Greg Gibson; Jeffrey S Hyams; Marla C Dubinsky
Journal:  Lancet       Date:  2017-03-02       Impact factor: 79.321

Review 6.  Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives.

Authors:  Niels Vande Casteele; Brian G Feagan; Ann Gils; Séverine Vermeire; Reena Khanna; William J Sandborn; Barrett G Levesque
Journal:  Curr Gastroenterol Rep       Date:  2014-04

7.  Value of drug level testing and antibody assays in optimising biological therapy.

Authors:  Séverine Vermeire; Ann Gils
Journal:  Frontline Gastroenterol       Date:  2012-09-05

Review 8.  Optimizing the use of biological therapy in patients with inflammatory bowel disease.

Authors:  Alan C Moss
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-01-06

9.  Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases.

Authors:  Karin Malíčková; Dana Ďuricová; Martin Bortlík; Ivana Janatková; Tomáš Zima; Milan Lukáš
Journal:  Auto Immun Highlights       Date:  2012-12-23

10.  Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization.

Authors:  Ann Gils; Niels Vande Casteele; Raf Poppe; Marlies Van de Wouwer; Griet Compernolle; Miet Peeters; Els Brouwers; Séverine Vermeire; Nick Geukens; Paul J Declerck
Journal:  Ther Drug Monit       Date:  2014-10       Impact factor: 3.681
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.